<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Investment Committee Memorandum — Multi-Service Medispa</title>
    <style>
      :root {
        --ink: #0f172a;
        --muted: #475569;
        --accent: #0f766e;
        --accent-ink: #0b5c56;
        --bg: #ffffff;
        --rule: #e2e8f0;
        --light: #f8fafc;
      }
      @page {
        size: Letter;
        margin: 15mm 12mm;
      }
      @media print {
        .no-print {
          display: none !important;
        }
        header,
        footer {
          position: fixed;
          left: 0;
          right: 0;
        }
        header {
          top: 5mm;
        }
        footer {
          bottom: 5mm;
        }
        .pb {
          page-break-before: always;
        }
      }
      body {
        font:
          11.5px/1.4 'Inter',
          system-ui,
          -apple-system,
          Arial,
          sans-serif;
        color: var(--ink);
        background: var(--bg);
        margin: 0;
        padding: 12px;
      }
      .header {
        display: grid;
        grid-template-columns: 1fr auto;
        align-items: end;
        border-bottom: 2px solid var(--accent);
        padding-bottom: 6px;
        margin-bottom: 12px;
      }
      .brand {
        font-weight: 700;
        color: var(--accent);
        font-size: 12px;
        text-transform: uppercase;
      }
      .doc-title {
        font-weight: 800;
        font-size: 16px;
        color: var(--ink);
        margin: 2px 0 0 0;
      }
      .meta {
        text-align: right;
        color: var(--muted);
        font-size: 10px;
      }

      .recommendation {
        background: linear-gradient(90deg, var(--light) 0, transparent 100%);
        border-left: 4px solid var(--accent);
        padding: 8px 12px;
        margin: 8px 0;
        border-radius: 4px;
      }
      .rec-badge {
        background: var(--accent);
        color: white;
        padding: 3px 8px;
        border-radius: 12px;
        font-weight: 600;
        font-size: 10px;
        margin-right: 8px;
      }

      .kpi-row {
        display: flex;
        gap: 8px;
        margin: 8px 0;
        flex-wrap: wrap;
      }
      .kpi {
        border: 1px solid var(--rule);
        border-radius: 6px;
        padding: 6px 8px;
        min-width: 110px;
        flex: 1;
      }
      .kpi-label {
        color: var(--muted);
        font-size: 9px;
        margin-bottom: 2px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }
      .kpi-value {
        font-weight: 700;
        color: var(--ink);
        font-size: 13px;
      }

      .grid {
        display: grid;
        grid-template-columns: 1fr 1fr;
        gap: 12px;
        margin: 10px 0;
      }
      .grid-3 {
        display: grid;
        grid-template-columns: 1fr 1fr 1fr;
        gap: 10px;
        margin: 8px 0;
      }

      h2 {
        font-size: 12px;
        font-weight: 700;
        color: var(--accent-ink);
        margin: 12px 0 6px 0;
        border-bottom: 1px solid var(--rule);
        padding-bottom: 2px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }
      h3 {
        font-size: 11px;
        font-weight: 600;
        margin: 8px 0 4px 0;
        color: var(--ink);
      }
      p {
        margin: 4px 0;
        font-size: 11px;
      }
      .small {
        font-size: 10px;
        color: var(--muted);
      }

      .table {
        width: 100%;
        border-collapse: collapse;
        margin: 6px 0;
        font-size: 10px;
      }
      .table th {
        text-align: left;
        color: var(--muted);
        font-weight: 600;
        font-size: 9px;
        border-bottom: 1px solid var(--rule);
        padding: 4px 4px 4px 0;
      }
      .table td {
        padding: 3px 4px 3px 0;
        border-bottom: 1px dashed #eef2f7;
      }
      .num {
        text-align: right;
        font-variant-numeric: tabular-nums;
      }
      .bold {
        font-weight: 700;
      }

      .callout {
        border: 1px solid var(--rule);
        border-left: 3px solid var(--accent);
        border-radius: 4px;
        padding: 6px 8px;
        background: #fbfdff;
        margin: 6px 0;
        font-size: 10px;
      }

      ul {
        margin: 4px 0 6px 14px;
        font-size: 10px;
      }
      li {
        margin: 2px 0;
      }

      .terms-table {
        font-size: 10px;
      }
      .terms-table td {
        padding: 2px 4px 2px 0;
        border-bottom: 1px dashed var(--rule);
      }

      .footer-note {
        margin-top: 8px;
        color: var(--muted);
        font-size: 9px;
        font-style: italic;
        border-top: 1px solid var(--rule);
        padding-top: 6px;
      }
    </style>
  </head>
  <body>
    <div class="header">
      <div>
        <div class="brand">CPP Investment Committee</div>
        <div class="doc-title">
          Investment Memorandum — Multi-Service Medispa
        </div>
        <div class="small">
          Single-Site Healthcare Services • All figures in
          <strong>$000s</strong>
        </div>
      </div>
      <div class="meta">
        <div><strong>From:</strong> Drew Williams (M&A)</div>
        <div><strong>Date:</strong> July 28, 2025</div>
        <div><strong>Subject:</strong> IOI Recommendation</div>
      </div>
    </div>

    <!-- RECOMMENDATION -->
    <div class="recommendation">
      <span class="rec-badge">RECOMMENDATION</span>
      <strong
        >Submit IOI at 7.0× Adj. EBITDA ($688), structured 70% Cash / 30%
        Roll</strong
      >, contingent upon QoE confirmation and verification of debt-like items.
    </div>

    <!-- KEY METRICS -->
    <div class="kpi-row">
      <div class="kpi">
        <div class="kpi-label">Enterprise Value</div>
        <div class="kpi-value">$4,813</div>
      </div>
      <div class="kpi">
        <div class="kpi-label">Net Debt (inferred)</div>
        <div class="kpi-value">$1,948</div>
      </div>
      <div class="kpi">
        <div class="kpi-label">Equity Value</div>
        <div class="kpi-value">$2,865</div>
      </div>
      <div class="kpi">
        <div class="kpi-label">Cash at Close</div>
        <div class="kpi-value">$2,006</div>
      </div>
      <div class="kpi">
        <div class="kpi-label">Rollover</div>
        <div class="kpi-value">$860</div>
      </div>
      <div class="kpi">
        <div class="kpi-label">Multiple</div>
        <div class="kpi-value">7.0×</div>
      </div>
    </div>

    <div class="grid">
      <!-- LEFT COLUMN -->
      <div>
        <h2>Financial Normalization</h2>
        <table class="table">
          <thead>
            <tr>
              <th>Bridge to Adj. EBITDA (2024)</th>
              <th class="num">Amount</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Revenue</td>
              <td class="num">$3,726</td>
            </tr>
            <tr>
              <td>Gross Profit (~70%)</td>
              <td class="num">$2,623</td>
            </tr>
            <tr>
              <td>S&M (normalized to 10% rev)</td>
              <td class="num">($373)</td>
            </tr>
            <tr>
              <td>Owner add-back</td>
              <td class="num">+300</td>
            </tr>
            <tr>
              <td>Interest reclass + Depreciation</td>
              <td class="num">+330</td>
            </tr>
            <tr>
              <td class="bold">Adjusted EBITDA</td>
              <td class="num bold">$688</td>
            </tr>
          </tbody>
        </table>

        <div class="callout">
          <strong>Coverage:</strong> ND/EBITDA = 2.8×; EBITDA/Interest = 3.5×<br />
          <strong>Net debt basis:</strong> Interest $195 ÷ 10% cost = $1,948
          (replaced by actual schedules in DD)
        </div>

        <h2>Valuation Sensitivity</h2>
        <table class="table">
          <thead>
            <tr>
              <th>EBITDA × Multiple</th>
              <th class="num">6×</th>
              <th class="num">7×</th>
              <th class="num">8×</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Base ($688)</td>
              <td class="num">2,180</td>
              <td class="num bold">2,865</td>
              <td class="num">3,556</td>
            </tr>
            <tr>
              <td>±10% ($619-$757)</td>
              <td class="num">1,767-2,593</td>
              <td class="num">2,386-3,350</td>
              <td class="num">3,006-4,106</td>
            </tr>
          </tbody>
        </table>

        <div class="callout">
          <strong>Marketing sensitivity:</strong> ΔEquity per 1% = Multiple ×
          (1% × Revenue)<br />
          At 7×: ≈$261 per 1% marketing increase (assumes no revenue response)
        </div>
      </div>

      <!-- RIGHT COLUMN -->
      <div>
        <h2>Investment Rationale</h2>
        <p>
          <strong>Supports 7× multiple:</strong> Cash-pay revenue model, ~70%
          gross margins, recurring injectables mix, established patient base.
        </p>
        <p>
          <strong>Risk factors:</strong> Single-site concentration, key provider
          dependency, device uptime requirements limit to mid-range multiple.
        </p>
        <p>
          <strong>70/30 structure:</strong> Balances seller liquidity with
          management retention/alignment for near-term execution.
        </p>

        <h2>Key Risks & Mitigations</h2>
        <div class="grid-3">
          <div>
            <h3>Provider Risk</h3>
            <ul>
              <li>Rollover alignment (30%)</li>
              <li>Employment contracts</li>
              <li>Stay bonuses</li>
            </ul>
          </div>
          <div>
            <h3>Device Risk</h3>
            <ul>
              <li>Uptime SLAs</li>
              <li>Maintenance reserves</li>
              <li>Downtime KPIs</li>
            </ul>
          </div>
          <div>
            <h3>Market Risk</h3>
            <ul>
              <li>Pricing governance</li>
              <li>Marketing ROAS</li>
              <li>Membership programs</li>
            </ul>
          </div>
        </div>

        <h2>Critical DD Priorities (30-45 Days)</h2>
        <ul>
          <li>
            <strong>QoE:</strong> Validate $688 EBITDA; seasonality; revenue
            recognition
          </li>
          <li>
            <strong>Debt/NWC:</strong> Loan schedules; payoff letters; working
            capital peg
          </li>
          <li>
            <strong>Operations:</strong> Provider agreements; device uptime
            logs; marketing analytics
          </li>
        </ul>

        <h2>Proposed IOI Terms</h2>
        <table class="terms-table">
          <tr>
            <td><strong>Valuation:</strong></td>
            <td>7.0× Adjusted EBITDA (base $688)</td>
          </tr>
          <tr>
            <td><strong>Consideration:</strong></td>
            <td>70% Cash / 30% Roll (off equity at close)</td>
          </tr>
          <tr>
            <td><strong>Conditions:</strong></td>
            <td>QoE confirmation; debt verification</td>
          </tr>
          <tr>
            <td><strong>Exclusivity:</strong></td>
            <td>45 days for confirmatory diligence</td>
          </tr>
        </table>
      </div>
    </div>

    <!-- PAGE BREAK FOR PAGE 2 IF NEEDED -->
    <div class="pb"></div>

    <h2>Executive Summary — Key Decision Points</h2>

    <div class="grid">
      <div>
        <h3>✅ Investment Thesis</h3>
        <ul>
          <li>
            <strong>Attractive financials:</strong> 18.5% EBITDA margin, 70% GP,
            cash-pay model
          </li>
          <li>
            <strong>Defensive characteristics:</strong> Recurring revenue,
            established patient base
          </li>
          <li>
            <strong>Operational leverage:</strong> Provider productivity,
            pricing optimization opportunities
          </li>
        </ul>

        <h3>⚠️ Key Concerns</h3>
        <ul>
          <li>
            <strong>Concentration risk:</strong> Single site, key provider
            dependency
          </li>
          <li>
            <strong>Operational risk:</strong> Device uptime critical to revenue
            generation
          </li>
          <li>
            <strong>Market risk:</strong> Marketing spend efficiency, seasonal
            variations
          </li>
        </ul>
      </div>

      <div>
        <h3>🎯 Value Creation Plan</h3>
        <h4>Day 1-30:</h4>
        <ul>
          <li>Payroll integration & comp ladder implementation</li>
          <li>Pricing governance & KPI instrumentation</li>
        </ul>

        <h4>Day 30-100:</h4>
        <ul>
          <li>Provider utilization optimization</li>
          <li>Membership program enhancement</li>
          <li>Marketing ROAS improvement</li>
        </ul>

        <h3>📊 Valuation Support</h3>
        <p>
          <strong>Multiple range 6-8×:</strong> Peer comparables, precedent
          transactions, DCF analysis all support 7× anchor within industry band.
        </p>
        <p>
          <strong>Marketing normalization:</strong> 10% of revenue standard for
          sustainable lead generation vs. 1% reported spend.
        </p>

        <h2>Investment Analysis Summary</h2>

        <h3>Key Concerns (Case Breakers)</h3>
        <ul>
          <li>Seasonality; risk 10% S&M insufficient to maintain lead flow</li>
          <li>Device downtime >10% for 30+ days</li>
          <li>Key-provider dependency: injector churn >15% in first 90 days</li>
        </ul>

        <h3>Growth Opportunities</h3>
        <ul>
          <li>Memberships & pricing governance to lift LTV and revenue/hour</li>
          <li>
            Injector productivity ladder (utilization, mix, scheduling
            discipline)
          </li>
        </ul>

        <h3>EBITDA Adjustments Rationale</h3>
        <ul>
          <li>
            S&M to 10% rev; owner +$300; remove one-offs; reclass interest; add
            back depreciation → <strong>$688</strong>
          </li>
        </ul>

        <h3>Multiple Justification</h3>
        <ul>
          <li>
            <strong>7.0×</strong> (band 6–8×) — cash-pay, ~70% GP, recurring mix
            vs single-site risk
          </li>
        </ul>

        <h3>Alternative Valuation Methods</h3>
        <ul>
          <li>
            EPV, simple DCF, comps/precedents bracket 6–8×; support 7× midpoint
          </li>
        </ul>

        <h3>Cash vs Equity Structure</h3>
        <ul>
          <li>
            70/30 improves retention/alignment; preserves growth capex and
            leverage headroom
          </li>
        </ul>

        <h3>Owner Compensation Treatment</h3>
        <ul>
          <li>
            Keep market post-close comp; add back only the excess ($300).
            Producer continuity secured via employment + rollover
          </li>
        </ul>
      </div>
    </div>

    <div class="callout">
      <strong>Deal Economics Summary:</strong> At 7.0× multiple on $688
      normalized EBITDA, transaction generates $2,865 equity value with balanced
      70/30 cash/roll structure. ND/EBITDA of 2.8× provides appropriate leverage
      for healthcare services business.
    </div>

    <div class="footer-note">
      <strong>Committee Action Required:</strong> Approval to submit IOI at
      proposed terms, subject to satisfactory QoE and debt verification.<br />
      <strong>Next Steps:</strong> 45-day exclusivity for confirmatory
      diligence; definitive documentation; closing conditions satisfaction.
    </div>
  </body>
</html>
